(NVO) Novo Nordisk - Ratings and Ratios
Insulin, Glucagon, Obesity, Hemophilia, Growth Hormone
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 2.67% |
| Yield on Cost 5y | 5.19% |
| Yield CAGR 5y | 2.82% |
| Payout Consistency | 96.2% |
| Payout Ratio | 7.2% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 40.3% |
| Value at Risk 5%th | 58.3% |
| Relative Tail Risk | -11.96% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.42 |
| Alpha | -32.47 |
| CAGR/Max DD | -0.02 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.357 |
| Beta | 0.870 |
| Beta Downside | 0.923 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.50% |
| Mean DD | 24.27% |
| Median DD | 9.04% |
Description: NVO Novo Nordisk January 26, 2026
Novo Nordisk A/S (NYSE: NVO) is a Denmark-based, globally diversified pharma company that develops, manufactures, and sells prescription medicines across Europe, the Middle East, Africa, China (including Hong Kong and Taiwan), North America, and other international markets.
The firm operates two reporting segments: Diabetes & Obesity Care, which covers insulin, GLP-1 agonists, cardiovascular and emerging therapies; and Rare Disease, which focuses on rare blood and endocrine disorders plus hormone-replacement products. Its commercial portfolio also includes delivery devices such as insulin and growth-hormone pens, injection needles, and digital tools like the smart insulin pen and the Dose Check dose-guidance app.
In FY 2023 Novo Nordisk reported revenue of $27.2 billion, a 12 % YoY increase driven primarily by a 38 % surge in sales of its obesity drug Wegovy and a 9 % rise in insulin sales despite price-regulation pressures in Europe. As of Q4 2024, the company’s pipeline includes three late-stage GLP-1 candidates targeting obesity and cardiometabolic disease, with an estimated $5 billion in potential market value if approved.
Key economic drivers for Novo Nordisk include the continued global rise in diabetes prevalence (projected to affect 10.9 % of adults by 2030) and obesity rates, which expand the addressable market for its GLP-1 portfolio; however, pricing reforms in the EU and the United-States’ shift toward value-based contracts introduce upside-down risk to margins. The firm’s collaborations-UNICEF’s childhood-obesity initiative and Valo Health’s AI-driven cardiometabolic drug discovery-aim to diversify growth sources but carry execution uncertainty.
For a deeper, data-rich assessment of Novo Nordisk’s valuation dynamics, consider exploring the company’s profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income: 103.77b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -4.72 > 1.0 |
| NWC/Revenue: -16.63% < 20% (prev -4.88%; Δ -11.75% < -1%) |
| CFO/TA 0.24 > 3% & CFO 123.78b > Net Income 103.77b |
| Net Debt (69.13b) to EBITDA (163.70b): 0.42 < 3 |
| Current Ratio: 0.78 > 1.5 & < 3 |
| Outstanding Shares: last quarter (4.45b) vs 12m ago -0.31% < -2% |
| Gross Margin: 82.05% > 18% (prev 0.85%; Δ 8120 % > 0.5%) |
| Asset Turnover: 69.38% > 50% (prev 68.08%; Δ 1.30% > 0%) |
| Interest Coverage Ratio: 8.15 > 6 (EBITDA TTM 163.70b / Interest Expense TTM 17.96b) |
Altman Z'' 3.08
| A: -0.10 (Total Current Assets 181.88b - Total Current Liabilities 234.36b) / Total Assets 512.29b |
| B: 0.33 (Retained Earnings 168.53b / Total Assets 512.29b) |
| C: 0.32 (EBIT TTM 146.44b / Avg Total Assets 454.86b) |
| D: 0.50 (Book Value of Equity 169.90b / Total Liabilities 342.39b) |
| Altman-Z'' Score: 3.08 = A |
Beneish M -2.63
| DSRI: 1.14 (Receivables 92.37b/69.50b, Revenue 315.60b/270.58b) |
| GMI: 1.03 (GM 82.05% / 84.66%) |
| AQI: 1.29 (AQ_t 0.27 / AQ_t-1 0.21) |
| SGI: 1.17 (Revenue 315.60b / 270.58b) |
| TATA: -0.04 (NI 103.77b - CFO 123.78b) / TA 512.29b) |
| Beneish M-Score: -2.63 (Cap -4..+1) = A |
ValueRay F-Score (Strict, 0-100) 90.04
| 1. Piotroski: 7.0pt |
| 2. FCF Yield: 3.47% |
| 3. FCF Margin: 19.88% |
| 4. Debt/Equity: 0.60 |
| 5. Debt/Ebitda: 0.42 |
| 6. ROIC - WACC: 35.53% |
| 7. RoE: 66.95% |
| 8. Revenue Trend: 96.64% |
| 9. EPS Trend: 87.97% |
What is the price of NVO shares?
Over the past week, the price has changed by +5.44%, over one month by +22.10%, over three months by +20.97% and over the past year by -24.87%.
Is NVO a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 5
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the NVO price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 57.6 | -10% |
| Analysts Target Price | 57.6 | -10% |
| ValueRay Target Price | 62.8 | -1.8% |
NVO Fundamental Data Overview January 24, 2026
P/E Trailing = 17.0493
P/E Forward = 17.3611
P/S = 0.8762
P/B = 10.4175
P/EG = 2.6568
Revenue TTM = 315.60b DKK
EBIT TTM = 146.44b DKK
EBITDA TTM = 163.70b DKK
Long Term Debt = 89.18b DKK (from longTermDebt, last quarter)
Short Term Debt = 12.03b DKK (from shortTermDebt, last quarter)
Debt = 101.21b DKK (from shortLongTermDebtTotal, last quarter)
Net Debt = 69.13b DKK (from netDebt column, last quarter)
Enterprise Value = 1809.86b DKK (1741.23b + Debt 101.21b - CCE 32.58b)
Interest Coverage Ratio = 8.15 (Ebit TTM 146.44b / Interest Expense TTM 17.96b)
EV/FCF = 28.85x (Enterprise Value 1809.86b / FCF TTM 62.74b)
FCF Yield = 3.47% (FCF TTM 62.74b / Enterprise Value 1809.86b)
FCF Margin = 19.88% (FCF TTM 62.74b / Revenue TTM 315.60b)
Net Margin = 32.88% (Net Income TTM 103.77b / Revenue TTM 315.60b)
Gross Margin = 82.05% ((Revenue TTM 315.60b - Cost of Revenue TTM 56.66b) / Revenue TTM)
Gross Margin QoQ = 76.12% (prev 83.29%)
Tobins Q-Ratio = 3.53 (Enterprise Value 1809.86b / Total Assets 512.29b)
Interest Expense / Debt = 4.95% (Interest Expense 5.01b / Debt 101.21b)
Taxrate = 21.60% (5.51b / 25.52b)
NOPAT = 114.81b (EBIT 146.44b * (1 - 21.60%))
Current Ratio = 0.78 (Total Current Assets 181.88b / Total Current Liabilities 234.36b)
Debt / Equity = 0.60 (Debt 101.21b / totalStockholderEquity, last quarter 169.90b)
Debt / EBITDA = 0.42 (Net Debt 69.13b / EBITDA 163.70b)
Debt / FCF = 1.10 (Net Debt 69.13b / FCF TTM 62.74b)
Total Stockholder Equity = 155.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 22.81% (Net Income 103.77b / Total Assets 512.29b)
RoE = 66.95% (Net Income TTM 103.77b / Total Stockholder Equity 155.00b)
RoCE = 59.97% (EBIT 146.44b / Capital Employed (Equity 155.00b + L.T.Debt 89.18b))
RoIC = 44.36% (NOPAT 114.81b / Invested Capital 258.80b)
WACC = 8.83% (E(1741.23b)/V(1842.45b) * Re(9.12%) + D(101.21b)/V(1842.45b) * Rd(4.95%) * (1-Tc(0.22)))
Discount Rate = 9.12% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.34%
[DCF Debug] Terminal Value 75.78% ; FCFF base≈64.61b ; Y1≈67.40b ; Y5≈77.66b
Fair Price DCF = 325.1 (EV 1164.43b - Net Debt 69.13b = Equity 1095.30b / Shares 3.37b; r=8.83% [WACC]; 5y FCF grow 4.61% → 2.90% )
EPS Correlation: 87.97 | EPS CAGR: 96.11% | SUE: 1.50 | # QB: 1
Revenue Correlation: 96.64 | Revenue CAGR: 19.59% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=5.06 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=22.46 | Chg30d=+0.612 | Revisions Net=-1 | Growth EPS=-2.7% | Growth Revenue=-1.5%
Additional Sources for NVO Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle